Psoriatic arthritis Initial PBS authority application Supporting information form (PB105)

You must lodge this form for an adult patient starting initial PBS subsidised treatment with a biological agent. Where the term biological agent appears it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and ustekinumab only. This form must be completed by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis.

 

Page last updated: 6 May 2016

This information was printed Thursday 29 September 2016 from humanservices.gov.au/health-professionals/forms/pb105 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.